You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業(09939.HK)指其普克魯胺可顯著抑制感染新型肺炎男性患者病情
阿思達克 01-11 10:12
開拓藥業(09939.HK)公布,普克魯胺在治療COVID-19的臨床試驗(ClinicalTrials.gov識別碼:NCT04446429)中男性患者的最終結果顯示,普克魯胺可以顯著抑制感染COVID-19的男性患者的病情從輕度到重度轉變,並且對於短期給藥具有良好的安全性。

結果顯示,普克魯胺組134名男性患者30日內的住院率、ICU使用、機械通氣使用及死亡百分比分別為0%、0%、0%及0%,而128名男性對照組則為27.3%、14.1%、10.2%及1.6%。

另外,公司預期於今年2月完成女性患者的臨床試驗招募,並於3月前完成數據收集。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account